By ENS Economic Bureau
12 June, 2014 | HYDERABAD: Dr Reddy’s Laboratories Ltd (DRL) is aiming to emerge as one of the top five dermatology companies in India
over the next 5-7 years. The company, which is said to be building a robust pipeline of products, is targeting to capture a market share of 15-20 per cent from the less than 10% currently.
“We hope to see a 20 per cent growth in the dermatology over the next five to seven years as there is a huge potential in this
segment,’’ said Alok Sonig, Senior Vice President, Head, Indiabusiness, DRL. The company launched Melgian lotion, claimed to be the first peptide-based drug for Vitiligo, which is in-licensed from ISSAR Pharmaceuticals. It already has products for haircare and skincare. Vitiligo is a skin disease that leads to white patches on the body due to the loss of normal skin pigment called melanin.
“The launch of Melgain is the testimony for our future investments into dermatology segment”, he said.